Advanced Filters
noise

Groningen, Netherlands Clinical Trials

A listing of Groningen, Netherlands clinical trials actively recruiting patients volunteers.

Found 228 clinical trials
K Kristel Muijs

Prediction Models for Complications After CRT in Esophageal Cancer

The aim of this project is to develop and validate NTCP-models for complications after nCRT (and surgical resection), that can be uses for model-based dose optimization for PhRT and PRT, and for model-based selection for PRT, in patients with esophageal cancer

18 - 100 years of age All Phase N/A
K Karin Klooster, PhD

Bronchoscopic EmphysemA Treatment in THE NetherLands

Rationale: New bronchoscopic treatments for emphysema have shown promise in clinical trials, improving lung function, exercise capacity and possibly survival and are now being adopted by a number of centres in the Netherlands. It is important to ensure that the benefits seen in clinical trials are in fact reflected in …

years of age All Phase N/A
J J. Nuver, MD, PhD

Early Ageing During Therapy in AYA Cancer Patients

Longitudinal cohort study; measurements before start of systemic therapy and one year later.

18 - 39 years of age All Phase N/A
V Vincent E de Meijer, MD, PhD

Long-term Outcomes After Prolonged Dual Hypothermic Oxygenated Machine Perfusion of Donor Livers (DHOPEPROLONG)

End-ischemic dual hypothermic oxygenated machine perfusion (DHOPE) of human donor livers mitigates ischemia-reperfusion injury, resulting in a reduction of post-reperfusion syndrome, early allograft dysfunction and biliary complications, when compared with static cold storage. End-ischemic DHOPE can be used to prolong donor liver preservation time for up to 24 hours. According …

18 years of age All Phase N/A
F Frank vd Veerdonk, Prof. Dr.

Prospective Observational Trial of IAPA

A prospective multi-center observational study to assess the incidence of influenza-associated pulmonary aspergillosis (IAPA) in ICU patients and to identify host- and pathogen related risk factors for IAPA in EORTC negative ICU patients with severe influenza.

18 years of age All Phase N/A
J Jan-Stephan Sanders, MD, PhD

Incidence, Course and Outcome of ABMR in Kidney Transplantation

Rationale: Despite improved patient and graft survival in renal transplant recipients, still 20% of the patients reaches end-stage renal disease within 5 years after transplantation. Antibody-mediated rejection (ABMR) is one of the major causes of early graft loss and perhaps even more important of late deterioration of graft function Objective: …

18 years of age All Phase N/A
T T.Jeroen Hiltermann, MD

Clinical Validation and Benchmarking of Top PerformingctDNA Diagnostics - Stage III NSCLC

Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies. Currently, for non small cell lung cancer (NSCLC), the methods used to decide who gets additional post radical (surgery or definite chemo-radiotherapy) treatment are suboptimal. Some patients get too much treatment, …

18 years of age All Phase N/A
L Laurine T van der Wal, MSc

Breast Cancer Long-term Outcomes on Cardiac Functioning: a Longitudinal Study

Rationale: In addition to surgery, effective breast cancer (BC) treatment typically requires chemotherapy, radiotherapy, or both. However, it is still unclear whether patients with BC are at increased risk of long-term cardiac dysfunction due to the adverse effects of these therapies. In a cross-sectional study in primary care, a comparison …

years of age Female Phase N/A
D D. J. de Groot, MD, PhD

Gut Microbiome Dynamics in Metastasized or Irresectable Colorectal Cancer

In this study the characteristics and alterations of the gut microbiome during chemotherapy for metastasized or irresectable CRC are studied, as well as the relation between the gut microbiome and the effects of chemotherapy.

18 years of age All Phase N/A
A Anniek Reinhardt, MSc./Drs.

The MS-CEBA Study: Determining Cognitive, Energetic, Behavioural and Affective (CEBA) Profiles in Multiple Sclerosis

Multiple Sclerosis (MS) is an invalidating neurological disease known to cause physical symptoms, which usually are the main focus of treatment. However, non-physical, more neuropsychological, symptoms also frequently occur, concerning the Cognitive, Energetic, Behavioural and Affective (CEBA) domains. Symptoms in the CEBA domains are known to negatively affect societal participation, …

18 - 70 years of age All Phase N/A

Simplify language using AI